A stem cell startup at the Karolinska Institute in Stockholm is nearing mass production of mesenchymal stem cells (MSCs), heralding a potential 'inflection point' for medicine. MSCs, which are capable of reducing inflammation, repairing tissue, and modulating the immune system, hold promise for treating chronic diseases, delaying aging, and even preventing illness. Scientists at the institute are meticulously cultivating these cells in cleanrooms, envisioning a future where MSCs become a standard medical treatment. The company believes mass production will overcome current limitations and unlock the full potential of stem cell therapy.